baona / iStockphoto.com
With legal developments in the CRISPR field ramping up this year, LSIPR examines the current international landscape and the options for parties interested in using the gene-editing technology.
Genetically modified humans are no longer in the realm of fantasy, and neither is the patenting of the technology that makes this possible.
While the well known CRISPR/Cas9 dispute between the Broad Institute of Harvard and MIT on one side, and the University of California, Berkeley (UCB) and the University of Vienna on the other, has mainly been centred in the US, the technology is used globally. Being an exciting emerging invention, more and more companies are claiming the patent rights to it.
The CRISPR dispute has been one of the biggest clashes in the life sciences industry in the past few years. But many from outside the life sciences industry might find it challenging to understand why this technology has been so important to the parties involved.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at email@example.com.
If you have any technical issues please email tech support.
CRISPR, Genetically modified humans, Harvard, Cas9, USPTO, Broad institute, PTAB, UCB,